EP
AMLX icon

Essential Partners’s Amylyx Pharmaceuticals AMLX Stock Holding History

Essential Partners’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$437 Hold
15
– – ﹤0.01% 2434
2026
Q2 		$269 Hold
15
– – ﹤0.01% 2589
2026
Q1 		$209 Sell
15
-2
-12% -$28 ﹤0.01% 2600
2025
Q4 		$205 Buy
17
+1
+6% +$14 ﹤0.01% 2427
2025
Q3 		$217 Buy
+16
New +$151 ﹤0.01% 2388

Other funds holding AMLX

Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
PPWP
Premier Path Wealth Partners Madison, New Jersey $856M AUM 23.55% 1-Year Est. Return
Valeo Financial Advisors
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.15% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VSQM
V-Square Quantitative Management Chicago, Illinois $1.09B AUM 23.97% 1-Year Est. Return
Eastern Bank
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
MassMutual Private Wealth & Trust
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
CAIM
Catherine Avery Investment Management Longboat Key, Florida $116M AUM 31.75% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Essential Partners's AMLX Position: Q3 2026 in Review

Essential Partners held its Amylyx Pharmaceuticals (AMLX) position steady in Q3 2026 at 15 shares worth $437. The position accounts for ﹤0.01% of the portfolio, ranked #2434.

Essential Partners first reported a position in AMLX in Q3 2025 and has held it in 5 quarters since. 12 funds tracked by Wall St. Rank hold AMLX as of Q3 2026.

  • Essential Partners held 15 shares of Amylyx Pharmaceuticals worth $437 as of Q3 2026.
  • Essential Partners left its Amylyx Pharmaceuticals share count unchanged in Q3 2026.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2434 holding.
  • Essential Partners first reported a position in Amylyx Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • 12 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.